Forte Biosciences (FBRX) Operating Leases (2019 - 2020)
Forte Biosciences' (FBRX) quarterly Operating Leases came in at $3.9 million in Q1 2020, down 59.07% year-on-year from $9.6 million in Q2 2019, and down 2.86% on a QoQ basis from $4.0 million in Q4 2019.
Forte Biosciences (FBRX) Operating Leases (2019 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has 2 years of Operating Leases data on file, last reported at $3.9 million in Q1 2020.
- On a quarterly basis, Operating Leases fell 59.07% year-over-year to $3.9 million in Q1 2020; TTM through Mar 2020 was $3.9 million, a 59.07% decrease from a year earlier, with the FY2019 full-year figure at $4.0 million, changed N/A from the prior year.
- Operating Leases for Q1 2020 stood at $3.9 million, down from $4.0 million in the prior quarter.
- Over the last five years, Operating Leases for FBRX reached as high as $9.6 million in Q1 2019 and fell as low as $3.9 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 3.91 Mn |
| Dec 31, 2019 | 4.03 Mn |
| Sep 30, 2019 | 9.12 Mn |
| Jun 30, 2019 | 9.36 Mn |
| Mar 31, 2019 | 9.56 Mn |